956.8000 2.15 (0.23%)
NSE Jul 10, 2025 15:00 PM
Volume: 18,098
 

956.80
0.23%
ICICI Securities Limited
Tatva Chintan Pharma Chem’s (TATVA) performance showed signs of improvement in Q4FY25 on the revenue front, but lower gross profit marred profit recovery. TATVA is hopeful of a sharp recovery in FY26, as new products commercialise in PASC and SDA volume recovers.
Tatva Chintan Pharma Chem Ltd. has gained 47.36% in the last 3 Months
More from Tatva Chintan Pharma Chem Ltd.
Recommended